Real Life Assessment of Biologics Efficacy in Severe Chronic Rhinosinusitis With Nasal Polyps

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational

With a prevalence of 2-4% in western countries, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is of major concern regarding its substantial impact on the social and physical quality of life. So far, endoscopic sinus surgery remains the treatment of choice when the first line of medical treatment with corticosteroid has failed. During the last 15 years, several studies have shown that CRSwNP is associated with a T helper 2 (T2) immune response leading to B cell release of IgE, mucosal recruitment of eosinophils from bone marrow via Interleukin (IL)-5, IL-4 and IL-13 mediated chemoattractant production. New biologic agents capable of blocking T2 cytokines have been developed in the field of eosinophil-associated diseases, shifting the paradigm of treatment for patients with CRSwNP. In the near future, endotype profiling with accurate biomarkers will be mandatory to tailor the treatment of nasal polyposis with specific biologic therapies. Herein we propose a prospective study monitoring medical records of CRSwNP patients who undergo biologic treatments. The objectives are to assess treatment efficacy on quality of life, to report clinical and biological criteria for prescription and to measure tolerance and compliance.

Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No

• Patients of over 18-year old requiring a biologic treatment for CRswNP in accordance with its marketing approval

Other Locations
Hop Claude Huriez Chu Lille
Contact Information
Goeffrey Mortuaire, MD
Time Frame
Start Date: February 10, 2022
Estimated Completion Date: July 2027
Target number of participants: 100
Leads: University Hospital, Lille

This content was sourced from